ASCENT-1 trial (STX-003): what clinicians have said so far
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- NCT07751042 ↗
- Recruiting
- Strand Therapeutics Inc.
- Standard size, estimated: 151–300 verified statements once built
Discussed at: SITC 2026
We haven't built an HCP commentary report on ASCENT-1 (STX-003; STX-003 plus pembrolizumab in advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ASCENT-1 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 8 posts on X, typically up to 35 once built | |
| 1 YouTube video, typically up to 4 once built | |
| 1 podcast episode, typically up to 4 once built | |
| 1 video on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of STX-003 Delivered Intravenously in Patients With Advanced Solid Tumors as a Monotherapy or in Combination With Pembrolizumab
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- STX-003; KEYTRUDA®
- Arms
- Phase 1 Monotherapy · Experimental
- Phase 1 Combination (STX-003 with Pembrolizumab) · Experimental
- Phase 2 Monotherapy (STX-003) · Experimental
- Phase 2 Combination (STX-003 with Pembrolizumab) · Experimental
- Enrollment
- 220 (estimated)
- Primary outcomes
- Incidence of TEAEs, SAEs, and DLTs
- Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-003.
- Sponsor
- Strand Therapeutics Inc.
- Start
- Jun 30, 2026
- Primary completion
- Jul 17, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07751042 · updated Oct 27, 2026